European Journal of Cancer
Volume 36, Issue 16 , Pages 2044-2052 , October 2000

A clinical nomogram for predicting long-term survival in advanced colorectal cancer

Received 20 March 2000 ,Revised 19 June 2000 ,Accepted 20 July 2000.

References 

  1. Cancer of the large bowel — UK. Cancer research Factsheet 1993 (18.1).
  2. Cunningham D, Pyrhonen S, James RD, et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413–1418
  3. Scheithauer W, Rosen H, Kornek G-V, et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 1993;306:752–755
  4. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group . Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer (a randomised trial). J. Clin. Oncol. 1992;10:904–911
  5. Glimelius B, Hoffman K, Graf W, et al.  Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann. Oncol. 1995;6:267–274
  6. Allen-Mersh TG, Earlam S, Fordy C, et al.  Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  7. Advanced colorectal Cancer Meta-Analysis Project . Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer (evidence in terms of response rate). J. Clin. Oncol. 1992;10:896–903
  8. The Meta-analysis Group of Cancer . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 1998;16:301–308
  9. Ross P, Norman A, Cunningham D, et al.  A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann. Oncol. 1997;8:995–1001
  10. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 1997;350:681–686
  11. Chang AE, Steinberg S, Coulnane M, et al.  Determinants of survival in patients with unresectable colorectal liver metastases. J. Surg. Oncol. 1989;40:245–251
  12. Kemeny N, Niedzwiecki D, Shurgot B, et al.  Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer. 1989;63:742–747
  13. Rougier P, Milan C, Lazorthes F, et al.  Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br. J. Surg. 1995;82:1397–1400
  14. Findlay M, Hill M, Cunningham D, et al.  Protracted venous infusion 5-fluorouracil and interferon-α in advanced and refractory colorectal cancer. Ann. Oncol. 1994;5:239–243
  15. Cunningham D, Zalcberg JR, Rath U, et al.  Tomudex (ZD1694) (results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia). Eur. J. Cancer. 1995;31A:1945–1954
  16. Hill M, Norman A, Cunningham D, et al.  Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J. Clin. Oncol. 1995;13:1297–1302
  17. Hill M, Norman A, Cunningham D, et al.  Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumour response, survival, and quality of life in advanced colorectal cancer. J. Clin. Oncol. 1995;13:2317–2323
  18. Zalcberg JR, Cunningham D, Van Cutsem E, et al.  ZD1694 (a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer). J. Clin. Oncol. 1996;14:716–721
  19. Seymour MT, Slevin ML, Kerr DJ, et al.  Randomised trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J. Clin. Oncol. 1996;14:2280–2288
  20. Cunningham D, Ross P, Webb A, et al. Phase I dose finding study of irinotecan hydrochloride trihydrate (CPT-11) with tomudex (TX) in patients with 5-FU refractory colorectal cancer. Eur J Cancer 1997, 33, S172 (abstract 770).
  21. Millar A, Hoogstraten B, Staquent M, et al.  Reporting results of cancer treatment. Cancer. 1981;47:207–214
  22. National Cancer Institute guidelines for reporting adverse drug reactions. Bethesda MD, Division of Cancer Treatment, NCI, 1988.
  23. Hansen RM, Ryan L, Anderson T, et al.  Phase III study of bolus versus infusional fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl. Cancer Inst. 1996;88:668–674
  24. Webb A, Scott-Mackie P, Cunningham D, et al.  The prognostic value of CEA, betaHCG, AFP, CA125, CA19-9, and C-erb B-2, betaHCG immunohistochemistry in advanced colorectal cancer. Ann. Oncol. 1995;6:581–587
  25. Rougier P, Neoptolemos JP. The need for a multidisciplinary approach in the treatment of advanced colorectal cancer (a critical review from a medical oncologist and surgeon). Eur. J. Surg. Oncol. 1997;23:385–396
  26. Wagman LD, Kemeny MM, Leong L, et al.  A prospective, randomised evaluation of hepatic resection for colorectal cancer metastatic to the liver. J. Clin. Oncol. 1990;8:1885–1893
  27. Chen ET, Mohiuddin M, Brodovsky H, et al.  Downstaging of advanced rectal cancer following combined pre-operative chemotherapy and high-dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 1994;30:169–175
  28. Landry JC, Koretz MJ, Wood WC, et al.  Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma (phase I–II study). Radiology. 1993;188:423–426
  29. Rougier P, Van Cutsen E, Bajetta E, et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407–1412
  30. de Gramont A, Figer A, Seymour M, et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc Am Soc. Clin Oncol 1998, 17: 257a (abstract 985).
  31. Maindrault-Goebel F, de Gramont A, Louvet C, et al. Oxaliplatin with high-dose leucovorin (LV) and 5-fluorouracil (5FU) 48-hour infusion in pretreated metastatic colorectal cancer (FOLFOX6). Ann Oncol 1998, 9(Suppl. 4), S36, (abstract 173 P).

PII: S0959-8049(00)00286-0

European Journal of Cancer
Volume 36, Issue 16 , Pages 2044-2052 , October 2000

Article Tools

* Image Usage & Resolution